Positive results - chronic toxicity study of ATL1102 in MS

[MSUK]

Antisense Therapeutics Limited is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose)..... Read More - http://www.ms-uk.org/ATL1102

[eric593]

Is it China that is using monkeys in this study? I didn't think anyone used monkeys anymore in labs, I thought it was no longer permitted.

[CureOrBust]

Tread carefully on following this one. Implication to working in a similar way to natalizumab

VLA-4 blockade, as shown by monoclonal antibodies such as natalizumab, prevents activated lymphocytes from migrating into the CNS and significantly reduces disease activity in MS.

http://www.drugs.com/clinical_trials/at ... -5608.html